tbuckley/cabot-search huggingface dataset:
Schnitzler syndrome: validation and applicability of diagnostic criteria in real-life patients
Authors: L. Gusdorf, B. Asli, S. Barbarot, A. Néel, A. Masseau, X. Puéchal, J-E. Gottenberg, G. Grateau, C. Blanchard-Delaunay, R. Rizzi, F. Lifermann, X. Kyndt, F. Aubin, D. Bessis, T. Boye, S. Gayet, F. Rongioletti, E. Sauleau, J-P. Fermand, D. Lipsker
Journal: Allergy (2016)

Schnitzler syndrome is characterized by an urticarial rash, a monoclonal gammopathy, and clinical, histological, and biological signs of neutrophil-mediated inflammation. The aim of this study was to assess the applicability and validity of the existing diagnostic criteria in real-life patients.This multicentric study was conducted between 2009 and 2014 in 14 hospitals in which patients with Schnitzler syndrome or controls with related disorders were followed up. We compared the sensitivities and specificities and calculated the positive and negative predictive values of the Lipsker and of the Strasbourg criteria for the patients with Schnitzler syndrome and for the controls. We included 42 patients with Schnitzler syndrome, 12 with adult-onset Still's disease, 7 with cryopyrin-associated periodic disease, 9 with Waldenström disease, and 10 with chronic spontaneous urticaria.All patients with Schnitzler syndrome met the Lipsker criteria. According to the Strasbourg criteria, 34 patients had definite Schnitzler syndrome, five had probable Schnitzler syndrome, and three did not meet the criteria. One control met the Lipsker criteria and had probable Schnitzler syndrome according to the Strasbourg criteria. Sensitivity and specificity of the Lipsker criteria were 100% and 97%, respectively. For the Strasbourg criteria, sensitivity for definite and probable diagnosis was 81% and 93%, respectively, with a corresponding specificity of 100% and 97%.Diagnostic criteria currently in use to diagnose Schnitzler syndrome are reliable. More investigations must be done to attest their efficiency in patients with recent-onset manifestations.
P0418 : Generation and characterization of a myofibroblasts specific conditional Col3a1a-CreERT2 mouse model to study liver fibrosis
Authors: O. Molokanova, K. Schönig, S.-Y. Weng, X.-Y. Wang, S. Ohngemach, A. Nikolaev, A. Hörner, S. Lorenz, D. Strand, L. Eshkind, D. Schuppan
Journal: Journal of Hepatology (2015)
Adult Stem Cell Therapy and Heart Failure, 2000 to 2016
Authors: Patricia K. Nguyen, June-Wha Rhee, Joseph C. Wu
Journal: JAMA Cardiology (2016)

<h3>Importance</h3> Stem cell therapy is a promising treatment strategy for patients with heart failure, which accounts for more than 10% of deaths in the United States annually. Despite more than a decade of research, further investigation is still needed to determine whether stem cell regenerative therapy is an effective treatment strategy and can be routinely implemented in clinical practice. <h3>Objective</h3> To describe the progress in cardiac stem cell regenerative therapy using adult stem cells and to highlight the merits and limitations of clinical trials performed to date. <h3>Evidence Review</h3> Information for this review was obtained through a search of PubMed and the Cochrane database for English-language studies published between January 1, 2000, and July 26, 2016. Twenty-nine randomized clinical trials and 7 systematic reviews and meta-analyses were included in this review. <h3>Findings</h3> Although adult stem cells were once believed to have the ability to create new heart tissue, preclinical studies suggest that these cells release cardioprotective paracrine factors that activate endogenous pathways, leading to myocardial repair. Subsequent randomized clinical trials, most of which used autologous bone marrow mononuclear cells, have found only a modest benefit in patients receiving stem cell therapy. The lack of a significant benefit may result from variations in trial methods, discrepancies in reporting, and an overreliance on surrogate end points. <h3>Conclusions and Relevance</h3> Although stem cell therapy for cardiovascular disease is not yet ready for routine clinical application, significant progress continues to be made. Physicians should be aware of the current status of this treatment so that they can better inform their patients who may be in search of alternative therapies.
The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer.
Authors: C. H. Lieu, H. T. Tran, Z. Jiang, M. Mao, M. J. Overman, C. Eng, J. Morris, L. M. Ellis, J. Heymach, S. Kopetz
Journal: Journal of Clinical Oncology (2011)

3533 Background: Circulating angiogenic factors have been previously shown to be altered in patients (pts) with mCRC on bevacizumab (BV)-containing regimens. However, a systematic evaluation of alterations in levels of the VEGF family of ligands may provide insights into resistance mechanisms. Methods: 42 patients (pts) with mCRC were treated on a single arm phase II study with 5-FU, irinotecan, and BV (FOLFIRI+BV), and plasma was collected for cytokine levels. VEGF-C, VEGF-D, and PlGF were measured using ELISA (R&D) or suspension bead multiplex assay (BioRad). Plasma samples were obtained at baseline, prior to radiographic progression, and at the time of radiographic progression. In a retrospective larger cohort used for validation, plasma from 403 matched pts with mCRC were obtained prior to any chemotherapy or after progression on a regimen with or without bevacizumab. Comparisons were done by the two-sided, nonparametric Wilcoxon paired test. Results: Following FOLFIRI+BV treatment, VEGF-C was increased prior to progression and at the time of progression (+43% [p=0.045] and +72% [p=0.004], respectively), similar to previously reported changes in PlGF (+67%, p<0.001). Levels of VEGF-D were increased at the time of progression (+39%, p=0.04). In a larger validation cohort, compared with pre-chemotherapy plasma, samples obtained a median of 3 weeks after progression on a regimen with BV had lower levels of VEGF-C but higher levels of VEGF-D (only +6%, p=0.018) and PlGF (+32%, p<0.0001). When compared to pts receiving chemotherapy alone, pts receiving prior BV had significantly elevated levels of PlGF (+72%, p<0.0001) but not VEGF-C and VEGF-D (+5% and +7%, p=NS). Levels of PlGF and VEGF-D were negatively correlated with the time from last chemotherapy dose to sample collection (p<0.0001) suggesting that changes at the time of progression are transient. Conclusions: Increases in VEGF-D and PlGF were consistently observed after progression on chemotherapy and BV, while VEGF-C changes require further validation. These changes may be reversible after discontinuing therapy. VEGF family ligands other than VEGF itself are associated with BV-containing chemotherapy resistance in mCRC.
Association of DNA repair polymorphisms with chemotherapy response and survival in lung cancer patients
Authors: Gisela Werle-Schneider, Heike Dally, Siegfried Tuengerthal, Jurgen Fischer, Birgit Jaeger, Berthold Spiegelhalder, Lutz Edler, Helmut Bartsch, Peter Drings, Angela Risch
Journal: Cancer Research (2008)

5822   The X-ray cross-complementing gene XRCC1 and the excision repair cross-complementing group 2 gene ERCC2 (XPD) are involved in the repair of DNA modifications resulting from DNA-damaging agents used in cancer therapy. The present study investigated whether functional polymorphisms in XRCC1 and ERCC2 may influence chemotherapy response outcome and survival in lung cancer patients.  Chemotherapy response and overall survival (OS) was evaluated in a prospective cohort study, including 303 Caucasians with primary lung cancer. Response to first-line chemotherapy was assessed after the 2nd treatment cycle based on RECIST criteria. DNA isolated from peripheral blood was genotyped for XRCC1 (Arg280His and Arg399Gln) and ERCC2 (Asp312Asn) by fluorescence-based melting curve (LightCycler) analysis and for XRCC1 (Arg194Trp) and ERCC2 (Lys751Gln) by PCR-RFLP. Haplotypes were statistically inferred with an algorithm based on Bayesian inference using PHASE v 2.1 software. The risk of being a non-responder (chemotherapy resistance) was assessed by unconditional logistic regression and quantified using odds ratio (ORs). OS was evaluated using the Cox proportional hazards models with hazard ratios (HRs).  ERCC2 Gln751C/Asp312G haplotype was associated with a reduced risk (OR 0.54 95%CI 0.24-1.20) of being a non-responder in lung cancer patients. In the subgroup of patients receiving platinum-based therapy, the reduced risk was statistically significant (OR 0.23 95%CI 0.07-0.85). Males with ERCC2 Gln751C/Asp312G haplotype had a reduced risk for response failure (OR 0.45, 95%CI 0.18-1.11). Reduced OS (HR 2.40, 95%CI 1.29-4.48) was observed in lung cancer patients with the diplotype of ERCC2 Gln751C/Asp312G//Gln751C/Asn312A, when compared to homozygous carriers of ERCC2 Gln751A/Asp312G. This effect was statistically significant in small cell lung cancer (SCLC) patients (HR 2.78, CI 1.14-6.79), but not in non small cell lung cancer (NSCLC) patients (OR 1.65, CI 0.56-4.83).  In conclusion, ERCC2 haplotypes and diplotypes modified lung cancer chemotherapy response and outcome, while no significant effects were observed for XRCC1.  Supported in part by the “Deutsche Krebshilfe” and the “Verein zur Forderung der Krebsforschung in Deutschland e.V.
Psychological sequelae of toxic epidermal necrolysis: further insights
Authors: S. Walsh, T. Lew, H.Y. Lee
Journal: British Journal of Dermatology (2016)

Stevens–Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) may be considered the most dramatic of all dermatological emergencies, characterized by a cataclysmic immune response to a stimulus, most usually a drug, and widespread skin loss. It is, to the lay person, the stuff of horror movies. From this perspective, the conclusions of the valuable paper published in the BJD this month by Dodiuk‐Gad et al. are perhaps unsurprising: that is, survivors of SJS/TEN carry with them a burden of psychological morbidity in the aftermath of what is a devastating life event.1 Butt et al. were the first group to assess in a qualitative fashion the impact of TEN on survivors.2 3 The language and phraseology used by patients in these landmark papers were haunting: ‘what I looked like made people…disgusted and scared…as if I was turned in to a monster’; ‘I am scarred in my mind as well as scarred on my body…’. Lew et al. assessed the psychological sequelae of drug reaction with eosinophilia and systemic symptoms, another of the severe cutaneous adverse reaction (SCAR) syndromes, and found similar experiences of anxiety, depression and post‐traumatic stress disorder (PTSD) among survivors.4
Hemoglobin A<sub>1c</sub>Levels Among Patients With Diabetes Receiving Nonsurgical Periodontal Treatment
Authors: Iain L. C. Chapple, Wenche S. Borgnakke, Robert J. Genco
Journal: JAMA (2014)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Frozen cultural plasticity
Authors: Petr Houdek, Julie Novakova
Journal: Behavioral and Brain Sciences (2016)

Abstract We discuss cultural group selection under the view of the frozen plasticity theory and the different explanatory power and predictions of this framework. We present evidence that cultural adaptations and their influence on the degree of cooperation may be more complex than presented by Richerson et al., and conclude with the gene-environment-culture relationship and its impacts on cultural group selection.
Viral Vector-Based Targeting of miR-21 in Cardiac Nonmyocyte Cells Reduces Pathologic Remodeling of the Heart
Authors: Deepak Ramanujam, Yassine Sassi, Bernhard Laggerbauer, Stefan Engelhardt
Journal: Molecular Therapy (2016)

Systemic inhibition of miR-21 has proven effective against myocardial fibrosis and dysfunction, while studies in cardiac myocytes suggested a protective role in this cell type. Considering potential implications for therapy, we aimed to determine the cell fraction where miR-21 exerts its pathological activity. We developed a viral vector-based strategy for gene targeting of nonmyocyte cardiac cells in vivo and compared global to cardiac myocyte-specific and nonmyocyte-specific deletion of miR-21 in chronic left ventricular pressure overload. Murine moloney virus and serotype 9 of adeno-associated virus were engineered to encode improved Cre recombinase for genetic deletion in miR-21fl/fl mice. Pericardial injection of murine moloney virus-improved Cre recombinase to neonates achieved highly selective genetic ablation of miR-21 in nonmyocyte cardiac cells, identified as cardiac fibroblasts and endothelial cells. Upon left ventricular pressure overload, cardiac function was only preserved in mice with miR-21 deficiency in nonmyocyte cardiac cells, but not in mice with global or cardiac myocyte-specific ablation. Our data demonstrate that miR-21 exerts its pathologic activity directly in cardiac nonmyocytes and encourage further development of antimiR-21 therapy toward cellular tropism.
Acute Exacerbations and Lung Function Loss in Smokers with and without Chronic Obstructive Pulmonary Disease
Authors: Mark T. Dransfield, Ken M. Kunisaki, Matthew J. Strand, Antonio Anzueto, Surya P. Bhatt, Russell P. Bowler, Gerard J. Criner, Jeffrey L. Curtis, Nicola A. Hanania, Hrudaya Nath, Nirupama Putcha, Sarah E. Roark, Emily S. Wan, George R. Washko, J. Michael Wells, Christine H. Wendt, Barry J. Make
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

Rationale: Acute exacerbations of chronic obstructive pulmonary disease (COPD) increase the risk of death and drive healthcare costs, but whether they accelerate loss of lung function remains controversial. Whether exacerbations in subjects with mild COPD or similar acute respiratory events in smokers without airflow obstruction affect lung function decline is unknown.Objectives: To determine the association between acute exacerbations of COPD (and acute respiratory events in smokers without COPD) and the change in lung function over 5 years of follow-up.Methods: We examined data on the first 2,000 subjects who returned for a second COPDGene visit 5 years after enrollment. Baseline data included demographics, smoking history, and computed tomography emphysema. We defined exacerbations (and acute respiratory events in those without established COPD) as acute respiratory symptoms requiring either antibiotics or systemic steroids, and severe events by the need for hospitalization. Throughout the 5-year follow-up period, we collected self-reported acute respiratory event data at 6-month intervals. We used linear mixed models to fit FEV1 decline based on reported exacerbations or acute respiratory events.Measurements and Main Results: In subjects with COPD, exacerbations were associated with excess FEV1 decline, with the greatest effect in Global Initiative for Chronic Obstructive Lung Disease stage 1, where each exacerbation was associated with an additional 23 ml/yr decline (95% confidence interval, 2–44; P = 0.03), and each severe exacerbation with an additional 87 ml/yr decline (95% confidence interval, 23–151; P = 0.008); statistically significant but smaller effects were observed in Global Initiative for Chronic Obstructive Lung Disease stage 2 and 3 subjects. In subjects without airflow obstruction, acute respiratory events were not associated with additional FEV1 decline.Conclusions: Exacerbations are associated with accelerated lung function loss in subjects with established COPD, particularly those with mild disease. Trials are needed to test existing and novel therapies in subjects with early/mild COPD to potentially reduce the risk of progressing to more advanced lung disease.Clinical trial registered with www.clinicaltrials.gov (NCT 00608764).
Abstract 14145: Stroke Volume Index Predicts Mortality of Patients Undergoing Transcatheter Aortic Valve Implantation With Concomitant Mitral Regurgitation
Authors: Nikolaos Anousakis-Vlachochristou, Konstantinos Toutouzas, Maria Drakopoulou, Konstantinos Stathogiannis, George Latsios, Andreas Synetos, Eleftherios Tsiamis, Dimitris Tousoulis
Journal: Circulation (2015)

Introduction: Patients with severe aortic stenosis frequently suffer from concomitant mitral regurgitation (MR), which implicates cardiac hemodynamic and clinical status. Hypothesis: We assessed the hypothesis that moderate/severe MR increases mortality of patients undergoing trancatheter aortic valve implantation (TAVI) and evaluated the possible predicting ability of pre-implantation echocardiographic assessment. Methods: We prospectively enrolled 119 patients, retrieved clinical and echocardiographic data before and 6 months after TAVI and divided patients in two groups: none/mild and moderate/severe MR. Clinical follow-up performed in a two-year period. A low mean gradient was assumed when &lt;40 mmHg, a low stroke volume index (SVi) when &lt;35ml/m2 and a low ejection fraction when &lt;45%. Statistical analysis of all-cause mortality performed with the Kaplan-Meier method and further evaluated with Cox proportional hazards analysis. Results: Seventy six patients (64%) had none/mild and 43 (36%) had moderate/severe MR. The baseline characteristics where evenly distributed among groups except for gender, coronary artery disease, chronic obstructive pulmonary disease and pulmonary arterial systolic pressure. The median follow-up time was 23 months (mean 22±13 months). During follow-up period the cumulative probability for mortality was significantly different between groups (none/mild MR: 14.5%, moderate/severe MR: 34.9%, p=0.006). In multivariate analysis, low SVi predicted mortality adjusted for moderate/severe MR and the variables that differed at baseline [HR: 5.1, 95% CI (2.21, 11.92), p=0.001], while other echocardiographic variables did not contribute to the final model although significant in univariate analysis. Conclusions: Patients undergoing TAVI with concomitant moderate or severe MR had increased risk for mortality in a two-year period. Pre-implantation low stroke volume index independently predicted mortality.
Mortality Among Hispanics
Authors: Ariel Pablos-Méndez
Journal: JAMA (1994)

<h3>To the Editor.</h3> —Hispanic Americans remain an understudied population, an issue that has surfaced in<i>JAMA</i>and other journals. The US Department of Health and Human Services<i>Healthy People 2000</i>, which declared increasing life expectancy and decreasing inequality among subpopulations as the top health objectives for the nation, reports a higher life expectancy for Hispanics (75 years) than non-Hispanic blacks (68 years) and whites (74.4 years).<sup>1</sup>Sorlie et al<sup>2</sup>confirmed the lower mortality of Latino adults in the United States. These statistics seem paradoxical, however, given the lower income, education, and health access, and the risk factor profile of Hispanics.<sup>3</sup>The possibility of genetic or cultural factors accounting for a survival advantage is exciting, and the policy implications of these estimates are significant, yet readers and decision makers should keep in mind that conceptual and operational problems plague research on race and ethnicity.<sup>4</sup> Two methodologic issues
Dietary Cholesterol and Blood Cholesterol Concentrations—Reply
Authors: Dariush Mozaffarian, David S. Ludwig
Journal: JAMA (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Selective Inhibitor Of Nuclear Exports (SINE) KPT-330 In Combination With The Novel Proteasome Inhibitor Carfilzomib As a Novel Therapeutic Regimen For Treating Aggressive B-Cell Lymphomas
Authors: Elyse R Lopez, Erin M Dominici, Muychi T Vang, Archito T. Tamayo, Zhishuo Ou, Alex Rollo, Liang Zhang, Jack Wang, Lauren M Strickland, Christopher J. Kirk, Michael Kauffman, Sharon Shacham, Michael Wang, Lan V Pham, Richard J. Ford
Journal: Blood (2013)